Nanopharm-logo-with-signature-Pantone (1)
Search
Close this search box.

30 May 2019

Mixed Kinetic Model of Inhaled Corticosteroid Dissolution

Share

This study investigates the dissolution kinetics of the poorly water-soluble active pharmaceutical ingredient fluticasone propionate. Dissolution is a key step in the delivery of drug molecules to their site of action and is often the rate-limiting step in their pharmacokinetics. The study found that the dissolution kinetics of fluticasone propionate aerosolised from a pressurised metered dose inhaler and three dry powder inhalers could not be described by a diffusion-limited model but could be described if surface transport kinetics were also incorporated. The use of this mixed kinetic control model allowed geometric parameters describing the dissolution process to be extracted which correlated well with measurements of the agglomeration state of the particles. The study suggests that more detailed kinetic models are required to understand the implications of dissolution kinetics on the rate at which poorly water-soluble active pharmaceutical ingredients become available at their site of action.

Related Posts

Innovation & Insights

Interview with Jane Provis Evans, Head cGMP services at Nanopharm

In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.

Read More »